L-carnitine supplementation ameliorates insulin resistance in critically ill acute stroke patients: a randomized, double-blinded,placebo-controlled clinical trial

Malihe Nejati , Saeed Abbasi, Shadi Farsaei , Fatemeh Shafiee

Abstract


Background and purpose: Insulin resistance (IR) can negatively affect clinical outcomes in acute ischemic stroke (IS) patients. Safe and cost-saving interventions are still needed to improve glycemic indices in this population. The primary objective was to evaluate L-carnitine (LC) effects in acute IS patients' homeostatic model assessment of IR (HOMA-IR).

Experimental approach: In this randomized, double-blind placebo-controlled clinical trial, critically ill IS patients were allocated to receive daily oral L-carnitine (1.5 g) or a placebo for six days. Fasting serum levels of glucose, insulin, C-reactive protein, LC, and HOMA-IR were measured on days 1 and 7. Mechanical ventilation duration, ICU/hospital duration, illness severity score, sepsis, and death events were assessed.

Findings/Results: Forty-eight patients were allocated to the research groups, 24 patients in each group, and all were included in the final analysis. LC administration showed a decrease in mean difference of HOMA-IR and insulin levels at day 7 compared to placebo, -0.94 ± 1.92 vs 0.87 ± 2.24 (P = 0.01) and -2.26 ± 6.81 vs 0.88 ± 4.95 (P = 0.03), respectively. However, LC administration did not result in significant improvement in clinical outcomes compared to placebo. The short duration of intervention and low sample size limited our results. 

Conclusion and implication: Supplementation of L-carnitine improved HOMA-IR index in acute IS patients admitted to the critical care unit. Supplementation of LC would be a potential option to help to control IR in critically ill acute IS patients.

 


Keywords


Keywords: Critical care; Insulin resistance, Ischemic stroke; L-carnitine, HOMA-IR, Hyperglycemia.

Full Text:

PDF

References


GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439-458.

DOI: 10.1016/S1474-4422(19)30034-1.

Islambulchilar M, Khoshsorour S, Sattari M, Ayramlo H. Evaluation of the changes in plasma concentrations of few free amino acids in ischemic and non-ischemic stroke patients. Res Pharm Sci. 2012;7(5):S145.

Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A, et al. Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke. Neurology. 2002;59(1):67-71.

DOI: 10.1212/WNL.59.1.67.

Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients a systematic overview. Stroke. 2001;32(10):2426-2432.

DOI: 10.1161/hs1001.096194.

Desilles JP, Meseguer E, Labreuche J, Lapergue B, Sirimarco G, Gonzalez VJ, et al. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke. 2013;44(7):1915-1923.

DOI: 10.1161/STROKEAHA.111.000813.

Shimoyama T, Kimura K, Uemura J, Saji N, Shibazaki K. Elevated glucose level adversely affects infarct volume growth and neurological deterioration in non-diabetic stroke patients, but not diabetic stroke patients. Eur J Neurol. 2014;21(3):402-410.

DOI: 10.1111/ene.12280.

Masrur S, Cox M, Bhatt DL, Smith EE, Ellrodt G, Fonarow GC, et al. Association of acute and chronic hyperglycemia with acute ischemic stroke outcomes post-thrombolysis: findings from get with the guidelines-stroke. J Am Heart Assoc. 2015;4:e002193,1-13.

DOI: 10.1161/JAHA.115.002193.

Calleja AI, Garcia-Bermejo P, Cortijo E, Bustamante R, Martinez ER, Gonzalez SE, et al. Insulin resistance is associated with a poor response to intravenous thrombolysis in acute ischemic strok. Diabetes Care. 2011;34(11):2413-2417.

DOI: 10.2337/dc11-1242.

Åberg D, Åberg ND, Jood K, Holmegaard L, Redfors P, Blomstrand P, et al. Homeostasis model assessment of insulin resistance and outcome of ischemic stroke in non-diabetic patients-a prospective observational study. BMC Neurol. 2019;19:177-185.

DOI: 10.1186/s12883-019-1406-3.

Ago T, Matsuo R, Hata J, Wakisaka Y, Kuroda J, Kitazono T, et al. Insulin resistance and clinical outcomes after acute ischemic strok. Neurology. 2018;90(17):e1470-e1477.

DOI: 10.1212/WNL.0000000000005358.

Johnston K, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke the shine randomized clinical trial. JAMA. 2019; 322(4):326-335.

DOI: 10.1001/jama.2019.9346.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321-1331.

DOI: 10.1056/NEJMoa1506930.

Alizadeh N, Khalili H, Mohammadi M, Abdollahi A, Ala S. Effect of vitamin D on stress-induced hyperglycaemia and insulin resistance in critically ill patients. Int J Clin Pract. 2016;70(5):396-405.

DOI: 10.1111/ijcp.12795.

Bakalar B, Duska F, Pachl J, Fric M, Otahal M, Pazout J, et al. Parenterally administered dipeptide alanyl-glutamine prevents worsening of insulin sensitivity in multiple-trauma patients. Crit Care Med. 2006;34(2):381-386.

DOI: 10.1097/01.CCM.0000196829.30741.D4.

Hejazi N, Mazloom Z, Zand F, Rezaianzadeh A, Nikandish R. The beneficial effects of α-lipoic acid in critically ill patients: a prospective, randomized, double-blind, placebo-controlled trial. Asian J Anesthesiol. 2018;56(2):45-55.

DOI: 10.6859/aja.201806_56(2).0002.

Heidary Z, Khalili H, Mohammadi M, Beigmohammadi MT, Abdollahi A. Effect of magnesium loading dose on insulin resistance in patients with stress-induced hyperglycemia: a randomized clinical trial. J Intensive Care Med. 2020;35(7):687-693.

DOI: 10.1177/0885066618777431.

Hatamkhani S, Karimzadeh I, Elyasi S, Farsaei S, Khalili H. Carnitine and sepsis: a review of an old clinical dilemma. J Pharm Pharm Sci. 2013;16:414-423.

DOI: 10.18433/j3js4c.

Khajeh B, Dashti-Khavidaki S, Nasiri-Toosi M, Mohammadi K, Jafari A. Effects of pre-transplant L-carnitine supplementation on primary graft dysfunction in liver transplant recipients: a pilot, randomized, placebo-controlled clinical trial. Res Pharm Sci. 2019;14(6):504-514.

DOI: 10.4103/1735-5362.272537.

Habibi Asl B, Taybey Khosrovshahy H, Ghanbarzadeh S. Comparison of the effect of erythropoietin and erythropoietin with oral solution of carnitine in treatment of anemia in hemodialysis patients. Res Pharm Sci. 2012;7(5):S921.

Xu Y, Jiang W, Chen G, Zhu W, Ding W, Ge Z, et al. L-carnitine treatment of insulin resistance: a systematic review and meta-analysis. Adv Clin Exp Med. 2017;26(2):333-338.

DOI: 10.17219/acem/61609.

Ringseis R, Keller J, Eder K. Role of carnitine in the regulation of glucose homeostasis and insulin sensitivity: evidence from in vivo and in vitro studies with carnitine supplementation and carnitine deficiency. Eur J Nutr. 2012;5(1):1-18.

DOI: 10.1007/s00394-011-0284-2.

Malaguarnera M, Vacante M, Motta M, Malaguarnerab M, Voltib GL, Galvanob F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism. 2009;58(11):1618-1623.

DOI: 10.1016/j.metabol.2009.05.014.

Bonafe L, Berger MM, Que YA, Mechanickc JI. Carnitine deficiency in chronic critical illness. Curr Opin Clin Nutr Metab Care. 2014;17(2):200-209.

DOI: 10.1097/MCO.0000000000000037.

Oami T, Oshima T, Hattori N, Teratani A, Honda S, Yoshida T, et al. L-carnitine in critically ill patients-a case series study. Ren Replace Ther. 2018;4:13-20.

DOI: 10.1186/s41100-018-0158-7.

Molfino A, Cascino A, Conte C, Ramaccini C, Rossi Fanelli F, Laviano A. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. JPEN J Parenter Enteral Nutr. 2010;34(3):295-299.

DOI: 10.1177/0148607109353440.

Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet. 2003;42(11):941-967.

DOI: 10.2165/00003088-200342110-00002.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28:412-419.

DOI: 10.1007/bf00280883.

Ascaso JF, Pardo S, Real JT, Lorente RI, Priego A, Carmena R. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. Diabetes Care. 2003;26(12):3320-3325.

DOI: 10.2337/diacare.26.12.3320.

Ghasemi A, Tohidi M, Derakhshan A, Hasheminia M, Azizi F, Hadaegh F. Cut-off points of homeostasis model assessment of insulin resistance, beta-cell function, and fasting serum insulin to identify future type 2 diabetes: Tehran lipid and glucose study. Acta Diabetol. 2015;52(5):905-915.

DOI: 10.1007/s00592-015-0730-3.

Lee S, Choi S, Kim HJ, Chung YS, Lee KW, Lee HC, et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci. 2006;21(4):695-700.

DOI: 10.3346/jkms.2006.21.4.695.

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8): 801-810.

DOI: 10.1001/jama.2016.0287.

Saberi F, Heyland D, Lam M, Rapson D, Jeejeebhoy KH. Prevalence, incidence, and clinical resolution of insulin resistance in critically ill patients: an observational study. JPEN J Parenter Enteral Nutr. 2008;32(3):227-235.

DOI: 10.1177/0148607108316195.

Harada S, Fujita-Hamabe W, Tokuyama S. Ischemic stroke and glucose intolerance: a review of the evidence and exploration of novel therapeutic targets. J Pharmacol Sci. 2012;118(1):1-13.

DOI: 10.1254/jphs.11R04CR.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.